Navicixizumab (Anti-DLL4 & VEGF)
Product Specifications
CAS Number
1638338-43-8
Synonyms
OMP 305B83
Target
VEGFR
Applications
Protein Tyrosine Kinase
Additionnal Information
Navicixizumab is a bispecific monoclonal antibody targeting DLL4 and VEGF, with potential anti-angiogenic and antineoplastic activities. It has shown antitumor effects in multiple cancer types, with the most promising results in ovarian cancer. M.W 146.17 kDa
Storage Conditions
-80°C (avoid freeze-thaw cycles)
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC400017-500 1x 500 µL
Ep-CAM / CD326 (VU-1D9), CF640R conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC880257-100 1x 100 µL
Cytokeratin, HMW (AE-3), CF488A conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC940225-500 1x 500 µL
Major Vault Protein (MVP) (1032), CF594 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC740493-100 1x 100 µL
Moesin (MSN/493), CF740 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 